Selvita to Acquire Fidelta from Galapagos for ~$37M
Shots:
- Selvita to acquire 100% of the outstanding shares in Fidelta for $37.08M + customary adjustments for net cash & working capital
- The acquisition will expand Selvita’s integrated drug discovery services offering with the addition of Fidelta
- Fidelta will be fully consolidated under Selvita Group & will continue to operate under the Fidelta name. Fidelta will continue to perform drug discovery services for Galapagos for the next five years
Ref: GlobeNewswire | Image: Fidelta
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com